Additional Fields Sample Clauses

Additional Fields. Contracted price with state per contract terms Contract Price List price (Market + fee contracts use market price) List Price Purchase Order, Payment Card, Other Purchase Type Delivered date to customer Date Delivered Order date Order Date Number of items purchased/provided Volume Qty Description of unit of measure (see example) UOM Desc Unit of Measure UOM United Nations Standard Products and Services Code® UNSPSC Code® State Agencies, Universities, Political Subdivisions, Other Eligible Users Customer Name Additional detail for item Product Description Additional grouping for item Item SubCategory Description of the product category Item Category Manufacturer, Publisher, Provider MFG Given name of Item Item / Service Name Your product part number if applicable Part Number/SKU Company State Term Contract No. Address Contract Expiration Date City Reporting Date State Zip Code Contact State of FL Vendor # Email Reporting Period Quarter Calendar Fiscal Year CQ12007 FYQ12007 Sample Contact Phone Number Total Sales (List) $0.00 (Calculated automatically) EA - Each Total Sales (Contract) $0.00 CS - Case ID Part Number/SKU Model Number/ Product Description MFG Item Category Item SubCategory Item / Service Name Customer, Agency, or Other Eligible UNSPSC Code UOM Order Date Purchase Order No. List Price Net Price Total ListPrice Total Net Price Total List Price Contract Price Total Contract Pest Control Services Department of Management Services Page 1 of 1 Solicitation No: ITB 1372102103_U Attachment I State of Florida Savings/ Price Reductions Form Invitation to Bid/Request for Proposal/Invitation to Negotiate/SPA No. Bidder/Respondent is required to furnish the percent (%) savings in prices offered compared to retail, list, published or other usual and customary prices that would be paid by the purchaser without benefit of a contract resulting from this bid. DATE COMPETITIVE PRICES OFFERED AVERAGE % SAVINGS. HOW CAN WE VERIFY THE CLAIMED SAVINGS (example: retail or other usual and customary prices published at [url], or other source of benchmark prices)? AUTHORIZED SIGNATURE: TELEPHONE NUMBER: BIDDER/RESPONDENT NAME: IF CONTRACT AWARDED, STATE PURCHASING ANALYST/SPECIALIST TOOK THE FOLLOWING STEPS TO VERIFY SAVINGS: WHAT WERE THE RESULTS? PURCHASING ANALYST/SPECIALIST: Pest Control Services Department of Management Page 1 of 1 Solicitation No: ITB 13-72102103-U Attachment J State of Florida Vendor Certification Regarding Scrutinized Companies Lists Respondent V...
Sample 1Sample 2See All (6)
AutoNDA by SimpleDocs
Additional Fields. (a) From time to time scPharma may wish to Develop or commercialize a drug-device combination based on an existing Device for subcutaneous administration based on the SenseCore Technology in fields outside the then-current Field of Use, excluding the Excluded Field (“Additional Field”). In that event, scPharma will provide Sensile written notice of its intentions and the applicable Additional Field. Sensile will respond to such notice within [***] to: (i) if Sensile has an alternate business interest pertaining to a drug/device combination that would preclude scPharma’s development and commercialization plan, Sensile shall so inform scPharma, or (ii) if Sensile does not have such an interest, Sensile will send scPharma a notice of acceptance (“Notice of Acceptance”) and grant scPharma a period of exclusive evaluation and negotiation for [***], during which Sensile and its Affiliates will cooperate in good faith with scPharma with respect to the evaluation of the intended Product. In the event that the Development of any such Product requires additional Development activities, the Parties shall negotiate in good faith a Development Plan for such Product within [***] of the date of the Notice of Acceptance from Sensile and negotiate in good faith reasonable and customary Development charges that may apply. Any such Product shall be subject to the Per-Unit Fee set forth in Section 3.1(a).
Sample 1Sample 2Sample 3
Additional Fields. (i) Licensee shall initially conduct Discovery, Development, Commercialization and Manufacturing activities directed to Targets only with respect to Indications in the Field. After Licensee’s completion of a Phase II Study with respect to any Licensed Product directed to a specific Target in the Field, Licensee may engage in Discovery, Development, and/or Manufacturing activities directed to such Target for any Indication (each, an “Additional Indication”) in any Additional Field (if such Additional Field has not been the subject of Licensee’s exercise of a Field Option) without having to pay a Field Option Fee; provided, however, that (A) Licensee shall notify Alnylam of its extension of Discovery, Development and/or Manufacturing activities directed to such Target for such Additional Indication in such Additional Field, and (B) Licensee shall pay Alnylam the following amounts (which shall be in addition to any event payments which may be owed under Section 5.3 below and except as provided in clause (ii) below) upon achievement of the following events by Licensee, its Affiliates or Licensee Partners with respect to each such Additional Indication: Payment for Licensed Products Development Event: (in [**]): Initiation of Phase III for each Additional Indication $ [**] Filing of an NDA for each Additional Indication $ [**] Regulatory Approval for each Additional Indication $ [**]
Sample 1Sample 2
Additional Fields. Sinotau shall have the right of first refusal to negotiate with FluoroPharma a royalty bearing, exclusive, transferable, license in the Territory outside the Field under the Licensed Technology to develop, have developed, use and have used, offer for sale, have sold and sell and, make and have made Product outside the Field in the Territory as defined in Exhibit A hereto provided that, if Sinotau does not enter into an agreement with FluoroPharma on terms at least as favorable on the whole to FluoroPharma as those offered by the Third Party within fifteen (15) days after FluoroPharma offers such terms to Sinotau, FluoroPharma is free to enter into an Agreement with the Third Party on such terms or on terms suitable to FluoroPharma.
Sample 1Sample 2
Additional Fields. In the event ACIS grants a license to any third party to use the ACIS Technology with non-Microsoft Platforms, ACIS agrees to make available such additional license rights to VSI on terms no less favorable than those granted to such third party.
Sample 1Sample 2
Additional Fields. Takeda shall initially conduct Development, Commercialization and Manufacturing activities directed to Targets only with respect to Indications in the Field. Based on the results of [**] with respect to any Licensed Product directed to a specific Target in the Field, Takeda may engage in Development, Commercialization and/or Manufacturing activities directed to such Target for any additional or replacement Indication (each, an “Additional Indication”) in any Additional Field not previously the subject of Takeda’s exercise of a Field Option, without having to pay a Field Option Fee; provided, however, that (i) Takeda shall notify Alnylam of its extension of Development, Commercialization and/or Manufacturing activities directed to such Target for such Additional Indication in such Additional Field, and (ii) Takeda shall pay Alnylam the following amounts (which shall be in addition to any event payments which may be owed under Section 7.2) upon achievement of the following events by Takeda, its Affiliates or sublicensees with respect to each such Additional Indication in such Additional Field: With respect to the first Licensed Product for each such Additional Indication in such Additional Field: Payment for Development Event: Licensed Products: Initiation of Phase III for each Additional Indication $ [**] Acceptance of NDA filing in a Major Market for each Additional Indication $ [**] First Commercial Sale in a Major Market for each Additional Indication $ [**] With respect to the second and each subsequent Licensed Product for such Additional Indication in such Additional Field: Payment for Development Event: Licensed Products: Initiation of Phase III for each Additional Indication $ [**] Acceptance of NDA filing in a Major Market for each Additional Indication $ [**] First Commercial Sale in a Major Market for each Additional Indication $ [**] The amounts paid under this Section 3.8(a) for Additional Indications within a given Additional Field shall be fully creditable against Field Option Fees which may be paid by Takeda pursuant to Section 7.4 for such Additional Field. In the event that the total event payments made under this Section 3.8(a) reach Fifty Million United States dollars ($50,000,000) for a given Additional Field, such Additional Field shall automatically be included in the Field hereunder. Amounts paid under this Section 3.8(a) with respect to Shared Products will be reduced by [**] percent ([**]%); provided that, for purposes of the credi...
Sample 1
Additional Fields. Habitat Pick the habitat that best describes the location. Options in upper case describe general habitats and options in lower case describe more specific habitats. If you feel the location does not fit into any of the categories below please record it as ‘other’ and specify in the comments box. 010 WETLAND 040 URBAN 070 SEMI-NATURAL WOODLAND 011 fen 041 park 071 deciduous 012 xxxx 042 orchard 072 coniferous 013 bog 043 churchyard 073 mixed deciduous/coniferous 020 HEATHLAND/MOORLAND 044 garden 080 PLANTATION WOODLAND 021 lowland wet heath 045 compost bin 081 deciduous 022 lowland dry heath 050 FARMLAND 082 coniferous 023 valley xxxx 051 arable 083 mixed deciduous/coniferous 024 upland heath/moor 052 pasture 090 BUILDING 030 GRASSLAND 060 SCRUBLAND 091 glasshouse (heated) 031 acid grassland 061 dense scrub 092 glasshouse (heated) 032 neutral grassland 062 scrub with open areas 100 CAVE/TUNNEL/WALL 033 calcareous grassland 110 WASTE GROUND 034 upland grassland 120 OTHER Substrate 301 rock 307 bark surface 313 fungi 302 stone 308 dead wood 314 nest (specify) 303 shingle 309 dead wood/under bark 315 shore line jetsam 304 soil/sand 310 xxxx/lichen 316 human rubbish 305 leaf litter 311 xxxx xxxxx 317 other (specify) 306 tussocks/clumps 312 xxxxxxx Method Different sampling methods will often yield different species as they may target different substrates or micro-habitats. 601 hand sorted soil pits (specify size) 605 Xxxxxxx bag 602 sieved leaf litter 606 pitfall trap 603 mustard extraction 607 ESB standard soil pits protocol 604 casual/turnover Comments Field The comment box should be used to record any data or information it was not possible to record in the other fields (for example additional habitat details or the size and number of soil pits per site). Where you have chosen an option that states ‘specify’, please enter the details in the comment box. Some earthworms exist in different morphs (for example Allolobophora chloritica occurs in a pink and a green form). If you are able to state what morph the species is please add this to the comments box. Altitude information can be attained through ordinance survey maps, GPS equipment or online tools (xxxx://xxx.xxxxxxxxx.xxx/sandbox-google-maps-find-altitude.htm). Any additional fields can be entered in here such as any notes regarding species of plant present, soil texture, soil pH, soil moisture, soil temperature, aspect and slope. Many sites across the UK are designated due to their importance to biodive...
Sample 1
AutoNDA by SimpleDocs
Additional Fields 
Sample 1Sample 2

Related to Additional Fields

  • Additional Products Upon satisfying the minimum order requirements above, Enrolled Affiliate may order Additional Products.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Development Milestone Payments In partial consideration for the rights and licenses granted to Coya hereunder, within ten days after the first achievement of each milestone event in a given Indication set forth in this Section 5.2 (Development Milestone Payments) with respect to a Product (each, a “Development Milestone Event”) by or on behalf of Coya or any of its Affiliates or Sublicensees, Coya shall provide ARScience Bio written notice to ARScience Bio identifying the Development Milestone Event achieved. Upon receipt of any such notice of first achievement of a Development Milestone Event by Coya or its Affiliates or Sublicensees, ARScience Bio will promptly invoice Coya for the applicable Development Milestone Event and Coya will make a milestone payment to ARScience Bio in the amount set forth in this Section 5.2 (Development Milestone Payments) corresponding to such Development Milestone Event (each, a “Development Milestone Payment”) within 45 days of receipt of such invoice. On an Indication-by-Indication basis, each Development Milestone Payment shall be payable only upon the first achievement of the corresponding Development Milestone Event by a Product, in any given Indication for which the Development Milestone Events have not been previously achieved (each such Indication, a “New Indication”). No amounts shall be due for subsequent or repeated achievements of such Development Milestone Event with respect to the same or different Mono Product or Combination Product, as applicable, in such Indication. Accordingly and for clarity, the Development Milestone Payment shall be paid only once, when first achieved by Coya, an Affiliate or a Sublicensee, but no payment shall be due if the same milestone is subsequently achieved by one of Coya, an Affiliate or a Sublicensee. For clarity, the amounts owed in Column (a) below shall be due for the first Combination Product to achieve the Development Milestone Events in a New Indication and the amounts owned in Column (c) below shall be due for the first Mono Product to achieve the Development Milestone Events in a New Indication. Any Combination Product or Mono Product to achieve the Development Milestone Events in a New Indication after the first achievement of the Development Milestone Events as described in the foregoing sentence will cause the amounts in Column (b) with respect to a Combination Product and Column (d) with respect to a Mono Product to be due and payable by Coya upon each such occurrence. If the first Product to achieve a Development Milestone Event in any Indication is a Combination Product, the amounts in Column (a) below shall be due and payable by Coya. If the next Product to achieve a Development Milestone Event in a New Indication is a Mono Product, the amounts in Column (c) below would be due and payable by Coya; provided, that if such next Product to achieve a Development Milestone Event in a New Indication is a Combination Product, the amounts in Column (b) would be due and payable by Coya. By way of example, if a Combination Product achieves IND Acceptance in ALS, and is the first Product to achieve a Development Milestone Event under this Agreement, [***] will be due and payable by Coya. If subsequently a Mono Product achieves IND Acceptance in ALS, no Development Milestone Payments will be due and payable by Coya under this Agreement. However, if subsequently any Combination Product achieves IND Acceptance in Alzheimer’s disease, [***] would be due and payable by Coya.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • ADDITIONAL ACTIVITIES I agree that during the period of my employment by the Company I will not, without the Company's express written consent, engage in any employment or business activity which is competitive with, or would otherwise conflict with, my employment by the Company. I agree further that for the period of my employment by the Company and for one (l) year after the date of termination of my employment by the Company I will not induce any employee of the Company to leave the employ of the Company.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Development Schedule The Project shall substantially comply with the specific timetables and triggers for action set forth in Article 5 of this Agreement. The parties acknowledge that, as provided in G.S. 160A-400.25(b), the failure to meet a commencement or completion date shall not, in and of itself, constitute a material breach of this Agreement pursuant to G.S. 160A-400.27 but must be judged based upon the totality of the circumstances.

  • Competing Products The provisions of Section 21 are set forth on attached Exhibit H and are incorporated in this Section 21 by this reference.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!